Moderna Brings Back Drug Product Manufacturing To Home Ground

• According to Moderna, the onshoring will support both commercial and clinical supply and create hundreds of jobs with over $140 million in investment. 
• The new investment is aimed at allowing the company to control the entire production process.
• Other popular pharma companies have also recently committed large amounts to expanding U.S. manufacturing, including Pfizer, Eli Lilly, and Johnson & Johnson.

Moderna, Inc. (MRNA) on Wednesday announced that it will bring drug product manufacturing to its existing Moderna Technology Center in Norwood, Massachusetts, as it seeks to operate end-to-end manufacturing for its mRNA medicines in the U.S.

"By onshoring Drug Product manufacturing to our campus in Norwood, Massachusetts, we have completed the full manufacturing loop under one roof in the U.S.," said CEO Stéphane Bancel. According to Cambridge-based Moderna, the onshoring will support both commercial and clinical supply and create hundreds of jobs with over $140 million in investment.

Timeline For New Facility

The company said it has commenced construction at the facility in Massachusetts to incorporate drug product manufacturing capability, which is slated for completion in the first half of 2027.

The move comes as the company seeks to reduce its reliance on contract manufacturers. The new investment is aimed at allowing the company to control the entire production process.

Other popular pharma companies have also recently committed large amounts to expanding U.S. manufacturing, including Pfizer, Eli Lilly, and Johnson & Johnson, as they seek to reduce reliance on overseas manufacturing.

Moderna’s mRNA Candidates

Moderna rose to fame during the COVID-19 pandemic with its mRNA-based vaccine Spikevax. In the third quarter of 2025, the company reported total revenue of $1 billion, down from $1.9 billion in the corresponding period of 2024, mainly due to lower COVID-19 vaccine sales.

However, Covid vaccine sales accounted for a whopping 97% of the company’s overall revenue in the three months through the end of September.

How Did Stocktwits Users React?

On Stocktwits, retail sentiment around MRNA stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.

MRNA stock is down 41% this year and 34% over the past 12 months. 

Also See: KZIA Stock Soars After Stage IV Cancer Patient Shows Initial Complete Remission On Its Drug Combination

For updates and corrections, email newsroom[at]stocktwits[dot]com

Share

·

Add us on